sever
acut
respiratori
syndrom
associ
coronaviru
main
proteas
sarscov
pro
propos
prime
target
antisar
drug
develop
clone
overexpress
sarscov
pro
escherichia
coli
purifi
recombin
pro
homogen
kinet
paramet
recombin
sarscov
pro
character
high
perform
liquid
chromatographybas
assay
continu
fluorescencebas
assay
two
novel
small
molecul
inhibitor
sarscov
pro
identifi
highthroughput
screen
use
intern
quench
fluorogen
substrat
identifi
inhibitor
k
valu
low
lm
rang
compar
antisarscov
activ
cellbas
assay
sever
acut
respiratori
syndrom
sar
swept
world
last
year
infect
peopl
across
countri
caus
fatal
etiolog
agent
sar
identifi
rapidli
novel
coronaviru
possibl
zoonot
origin
inadequ
knowledg
novel
coronaviru
sarscov
absenc
efficaci
therapeut
howev
main
reason
failur
improv
outcom
patient
manag
outbreak
sar
effect
similar
coronavirus
sarscov
envelop
positivestrand
rna
viru
larg
singlestrand
rna
genom
compris
nucleotid
among
variou
open
read
frame
identifi
replicas
gene
encod
two
overlap
polyprotein
compris
approxim
twothird
genom
sinc
viral
polyprotein
larg
process
main
proteas
pro
base
success
develop
efficaci
antivir
agent
target
proteas
virus
essenti
proteas
consid
prime
target
antisar
drug
develop
addit
recent
avail
crystal
structur
sarscov
pro
made
possibl
employ
structurebas
drug
design
develop
pro
specif
inhibitor
date
number
potenti
inhibitor
sarscov
propos
use
molecular
model
virtual
screen
techniqu
howev
inhibitori
activ
propos
inhibitor
yet
examin
vitro
assay
employ
purifi
sarscov
pro
synthet
substrat
tediou
procedur
involv
convent
high
perform
liquid
chromatographi
hplc
base
cleavag
assay
addit
hplcbase
cleavag
assay
impract
highthroughput
screen
ht
thousand
compound
chemic
librari
continu
fluorescencebas
assay
system
therefor
great
interest
field
rapid
screen
evalu
potenc
potenti
inhibitor
sarscov
pro
acquir
chemic
librari
chembridg
corpor
structur
divers
small
molecul
compound
vari
function
group
charg
divers
chemic
librari
purpos
chosen
antisar
drug
screen
sinc
set
isol
biolog
activ
small
molecul
perturb
variou
viral
compon
sarscov
cellular
model
infect
total
compound
protect
permiss
vero
cell
african
green
monkey
kidney
cell
sarscov
infect
identif
inhibitor
sarscov
pro
pool
compound
use
convent
hplcbase
assay
laborintens
time
consum
report
enzymat
character
recombin
sarscov
pro
authent
sarscov
pro
amino
acid
sequenc
employ
continu
fluorescencebas
assay
identifi
novel
small
molecul
inhibitor
sarscov
pro
efficaci
select
inhibitor
also
evalu
cellbas
antivir
assay
studi
defin
kinet
paramet
sarscov
pro
hplcbase
continu
fluorescencebas
assay
valid
use
fluorescencebas
assay
ht
result
also
provid
biolog
activ
novel
nonpeptid
lead
compound
ration
drug
design
sarscov
pro
inhibitor
clone
sarscov
pro
construct
plasmid
pet
svmp
sarscov
strain
rna
extract
cell
lysat
virusinfect
vero
cell
african
green
monkey
kidney
cell
line
trizol
invitrogen
accord
manufactur
instruct
revers
transcript
perform
use
thermoscript
rtpcr
system
purchas
invitrogen
fulllength
cdna
subsequ
amplifi
pcr
use
forward
primer
svmpf
revers
primer
svmpr
pcr
product
separ
agaros
gel
electrophoresi
purifi
use
qiaquick
gel
extract
kit
qiagen
digest
bamhi
ecori
restrict
endonucleas
ligat
bamhiecoridigest
dna
novagen
transform
e
coli
cell
electropor
gener
pet
svmp
nucleotid
sequenc
sarscov
pro
gene
plasmid
pet
svmp
sequenc
confirm
undesir
mutat
introduc
construct
design
way
factor
xa
cleavag
site
engin
nterminu
sarscov
pro
histag
iegr
sgfrkm
factor
xa
cleavag
site
indic
releas
ntermin
part
sarscov
pro
bold
cleavag
factor
xa
releas
histag
yield
recombin
sarscov
pro
authent
sarscov
pro
amino
acid
sequenc
ident
purifi
sarscov
pro
determin
mass
spectrometri
genom
research
centr
univers
hong
kong
escherichia
coli
gold
cell
novagen
transform
plasmid
pet
svmp
grown
shake
luriabertani
broth
contain
lgml
kanamycin
cultur
induc
mm
isopropyl
bd
thiogalactosid
iptg
grown
shake
h
cell
harvest
centrifug
g
min
disrupt
sonic
buffer
contain
mm
trishcl
ph
mm
nacl
lyse
cell
centrifug
g
min
supernat
decant
manipul
fusion
sarscov
pro
purifi
affin
purif
use
hitrap
tm
chelat
column
amersham
bioscienc
cleav
factor
xa
releas
ntermin
histag
recombin
sarscov
pro
amino
acid
sequenc
ident
authent
sarscov
pro
purifi
anionexchang
chromatographi
use
q
sepharos
fast
flow
column
amersham
bioscienc
follow
size
exclus
chromatographi
use
hiload
tm
superdex
column
amersham
bioscienc
synthet
peptid
sequenc
h
ntsavlq
sgfrkwcooh
mimick
autolyt
cleavag
site
cleavag
site
indic
ntermin
part
pro
synthes
synpep
corpor
cleavag
assay
first
carri
buffer
nm
purifi
sarscov
pro
lm
synthet
substrat
cleavag
product
resolv
hplc
use
sourc
tm
column
mm
mm
amersham
bioscienc
min
linear
gradient
acetonitril
trifluoroacet
acid
absorb
determin
nm
peak
area
integr
quantifi
cleavag
product
kinet
paramet
determin
lineweaverburk
plot
use
mm
synthet
substrat
nm
pro
ident
condit
ident
cleavag
product
confirm
mass
spectrometri
genom
research
centr
univers
hong
kong
synthet
fluorogen
peptid
dabcylsavlq
sgfrkedan
mimick
autolyt
cleavag
site
cleavag
site
sarscov
pro
indic
synthes
synpep
corpor
cleavag
fluorogen
peptid
monitor
continu
fluoresc
spectrophotomet
hitachi
use
excit
wavelength
nm
nm
slit
emiss
wavelength
nm
nm
slit
standard
assay
condit
buffer
initi
fluoresc
measur
substrat
concentr
lm
establish
linear
enzym
concentr
rate
cleavag
initi
rate
chang
fluoresc
measur
sever
sarscov
pro
concentr
nm
use
lm
fluorogen
peptid
substrat
assum
substrat
concentr
use
much
lower
k
sarscov
pro
determin
kinet
paramet
fluoresc
properti
substrat
use
follow
equat
f
fluoresc
intens
measur
given
time
reaction
f
intens
substrat
prior
addit
enzym
f
f
intens
product
substrat
cleav
suffici
pro
within
period
min
e
concentr
sarscov
pro
use
reaction
valu
k
cat
k
determin
either
nonlinear
least
squar
regress
analysi
data
use
eq
linear
least
squar
regress
analysi
initi
veloc
data
use
eq
ht
perform
quadrupl
black
polypropylen
plate
greiner
bioon
two
microlit
compound
mgml
dimethyl
sulfoxid
dmso
ad
individu
well
fifti
microlitersof
lm
fluorogen
peptid
buffer
deliv
well
liquid
dispens
genetix
reaction
initi
addit
nm
sarscov
pro
buffer
liquid
dispens
fluoresc
intens
measur
fusion
univers
plate
reader
perkinelm
life
scienc
use
excit
wavelength
nm
emiss
wavelength
nm
fluoresc
intens
chang
well
calcul
normal
mean
valu
compound
ad
determin
k
identifi
inhibitor
cleavag
assay
carri
buffer
contain
mm
trishcl
ph
mm
nacl
dmso
without
inhibitor
two
hundr
nanomolar
purifi
sarscov
pro
preincub
buffer
min
fluorogen
substrat
ad
final
concentr
lm
initi
reaction
valu
k
determin
nonlinear
least
squar
regress
analysi
data
fit
follow
equat
cat
k
cat
k
valu
presenc
absenc
inhibitor
respect
total
concentr
inhibitor
ad
least
six
concentr
inhibitor
use
obtain
final
k
valu
cellbas
antivir
assay
sarscov
strain
hku
isol
sar
patient
hong
kong
degre
protect
offer
test
compound
sarscov
infect
measur
vero
cell
cytopath
effect
cpe
assay
plaqu
reduct
assay
pra
cpe
assay
vero
cell
seed
cell
per
well
microtitr
plate
complet
eagl
minim
essenti
medium
emem
invitrogen
supplement
heatinactiv
fetal
bovin
serum
fb
invitrogen
without
addit
test
compound
one
hundr
tcid
tissuecultur
infecti
dose
sarscov
ad
subsequ
well
assay
plate
incub
co
cpe
infect
cell
record
h
post
infect
use
leica
dmil
invert
microscop
equip
digit
imag
system
leica
microsystem
pra
one
hundr
plaqu
form
unit
pfu
sarscov
ad
individu
well
tissu
cultur
plate
tpp
seed
confluent
monolay
vero
cell
cell
per
well
emem
fb
plate
incub
co
h
one
millilitr
overlay
lowmelt
agaros
emem
fb
appropri
concentr
inhibitor
ad
well
media
aspir
h
incub
co
cell
fix
ad
ml
formaldehyd
agaros
plug
remov
cell
stain
crystal
violet
methanol
viral
plaqu
count
experi
carri
quadrupl
dose
respons
data
best
fit
logist
equat
sigmaplot
spss
cytotox
inhibitor
determin
mtt
bromid
assay
roch
accord
manufactur
instruct
procedur
involv
manipul
live
sarscov
carri
biolog
safeti
level
contain
laboratori
pro
histag
recombin
sarscov
pro
success
express
e
coli
full
length
authent
sarscov
pro
purifi
homogen
affin
chromatographi
factor
xa
cleavag
anionexchang
chromatographi
sizeexclus
chromatographi
describ
protocol
yield
mg
purifi
protein
liter
cultur
employ
synthet
substrat
mimick
put
autolyt
cleavag
site
ntermin
part
pro
hplcbase
cleavag
assay
establish
specif
purifi
sarscov
pro
fig
turnov
number
sarscov
pro
k
synthet
peptid
found
ae
ae
respect
lineweaverburk
plot
k
cat
k
calcul
ae
fig
linear
initi
fluoresc
intens
gradual
lost
concentr
lm
fig
properti
similar
fluorogen
peptid
design
cytomegaloviru
cmv
proteas
lm
use
initi
rate
chang
fluoresc
intens
increas
linear
fashion
nm
sarscov
pro
fig
indic
use
use
fluorescencebas
substrat
conduct
kinet
studi
specifi
condit
use
lm
nm
sarscov
pro
k
cat
k
valu
ae
obtain
appli
eq
compound
screen
lgml
rate
chang
fluoresc
intens
normal
control
absenc
inhibitor
result
shown
fig
ten
compound
exhibit
greater
reduct
rate
chang
fluoresc
intens
compar
control
absenc
inhibitor
therefor
select
evalu
hit
expect
fals
posit
deliveri
error
light
scatter
optic
absorb
test
compound
final
evalu
inhibitor
perform
rigor
hplcbase
cleavag
assay
subject
artifact
compound
test
concentr
lgml
nm
sarscov
pro
lm
use
hplcbase
assay
two
exhibit
inhibitori
effect
pro
therefor
regard
true
inhibitor
data
shown
two
identifi
inhibitor
design
chemic
structur
shown
fig
determin
valu
k
concentr
inhibitor
convert
molar
unit
precis
comparison
inhibitori
activ
k
valu
calcul
appli
eq
ae
ae
lm
respect
use
fluorogen
substrat
tabl
lgml
concentr
inhibitor
protect
monolay
vero
cell
sarscov
induc
cpe
fig
indic
promis
antivir
activ
nontox
properti
two
compound
concentr
test
addit
inhibit
sarscov
plaqu
format
vero
cell
concentr
depend
manner
ec
median
effect
concentr
valu
ae
ae
lm
respect
tabl
demonstr
protect
effect
observ
inde
due
presenc
pro
inhibitor
furthermor
tc
median
toxic
concentr
valu
determin
lm
tabl
indic
two
compound
cytotox
effect
antivir
concentr
set
clone
character
sarscov
pro
intent
develop
assay
system
amend
ht
oper
isol
potenti
drug
lead
target
essenti
compon
sarscov
sinc
addit
amino
acid
sequenc
present
recombin
pro
result
clone
procedur
might
undesir
properti
vitro
vivo
assay
system
engin
recombin
sarscov
pro
way
final
purifi
recombin
sarscov
pro
amino
acid
sequenc
ident
authent
sarscov
pro
success
purif
employ
affin
chromatographi
factor
xa
cleavag
anionexchang
chromatog
raphi
sizeexclus
chromatographi
obtain
purifi
sarscov
pro
k
cat
k
valu
use
synthet
substrat
k
cat
k
valu
use
fluorogen
substrat
kinet
paramet
obtain
compar
viral
proteas
report
notic
k
cat
k
valu
calcul
publish
lai
group
synthet
peptid
substrat
h
ntsavlqsgfrkcooh
lower
one
obtain
synthet
peptid
substrat
h
ntsavlqsgfrkwcooh
k
cat
k
valu
asid
differ
purif
procedur
assay
condit
slight
differ
amino
acid
sequenc
two
peptid
explan
appar
discrep
result
obtain
two
group
fluorogen
substrat
use
studi
sensit
assay
cleavag
activ
sarscov
pro
littl
nm
sarscov
pro
could
detect
assay
system
employ
data
shown
ultrasensit
substrat
howev
could
use
concentr
higher
lm
due
intern
quench
effect
properti
render
unsuit
determin
k
assay
system
nevertheless
demonstr
excel
substrat
ht
purpos
evalu
inhibitor
potenc
two
small
molecul
compound
identifi
studi
novel
nonpeptid
inhibitor
sarscov
pro
fact
inhibit
sarscov
pro
k
valu
around
lm
protect
vero
cell
viral
infect
compar
concentr
exhibit
low
cytotox
toward
vero
cell
make
promis
lead
antisar
drug
develop
investig
use
analogu
two
sarscov
pro
inhibitor
suggest
posit
nitro
group
inhibitor
contribut
substanti
inhibitori
activ
chang
group
group
fig
readili
reduc
compound
abil
inhibit
sarscov
pro
fig
specul
group
may
involv
form
product
bond
inhibitorenzym
complex
structureact
relationship
studi
employ
analogu
identifi
compound
sitedirect
mutagenesi
sarscov
pro
help
us
elucid
mode
action
two
novel
inhibitor
manuscript
prepar
number
group
report
clone
product
differ
version
sarscov
pro
other
describ
develop
vitro
assay
screen
sarscov
pro
inhibitor
report
detail
kinet
analysi
recombin
sarscov
pro
amino
acid
sequenc
ident
authent
sarscov
pro
success
identif
potent
small
molecul
inhibitor
pro
demonstr
antisarscov
activ
cellular
model
establish
assay
system
examin
vitro
cleavag
cellular
antisarscov
activ
start
lead
optim
use
focus
combinatori
chemic
librari
understand
structureact
relationship
two
lead
yield
compound
far
superior
antivir
activ
